Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL Believe
NCT05081609Phase 2Active, not recruiting
- Sponsor
- Ascendis Pharma
- Start
- Jan 2022
- Primary completion
- Aug 2027
- Modality
- Cytokines & Interferons
- Countries
- 10
01
Overview
A Phase 2 trial of TransCon IL-2 β⁄γ in solid tumor, ovarian cancer, melanoma, Cervical Cancer (CC), non-small cell lung cancer (NSCLC), sponsored by Ascendis Pharma. Started Jan 2022; status: active, not recruiting.
02
Drugs
TransCon IL-2 β⁄γ
03
Conditions
solid tumorovarian cancermelanomaCervical Cancer (CC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05081609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081609.